The report provides a detailed analysis essential for establishing a patiromer production plant. It encompasses all critical aspects necessary for patiromer production, including the cost of patiromer production, patiromer plant cost, patiromer production costs, and the overall patiromer production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a patiromer production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Patiromer is a sodium-free potassium-binding polymer that is used to treat hyperkalemia (high blood potassium levels) in adults. It is used in patients with chronic kidney disease (CKD) on renin-angiotensin-aldosterone system inhibitors (RAASi) like ACE inhibitors or ARBs.
It works by binding potassium ions in the gastrointestinal tract, exchanging them for calcium, which promotes faecal excretion and lowers serum potassium levels. It is utilised for managing chronic hyperkalemia in patients with CKD, heart failure, hypertension, or diabetic kidney disease. It can reduce potassium in 4–52 weeks with a low risk of hypokalaemia. Its common side effects include constipation, hypomagnesemia, diarrhoea, nausea, abdominal discomfort and pain, flatulence, and occasionally hypokalaemia or vomiting.
The market for patiromer is fuelled by the increasing cases of hyperkalemia. Its utilisation in patients with chronic kidney disease (CKD), heart failure, , contribute to its demand. The expanding global approvals and favourable reimbursement decisions from bodies like UK NICE and France HAS expand its adoption. The high drug costs and pricing dynamics influenced by market competition, patent protections, and the presence of biosimilars influence industrial patiromer procurement. The established renal distribution network, strong long-term efficacy and safety from clinical trials further affect its sourcing. Other factors like reliable production through validated polymer synthesis and payer preferences for RAASi-enabling options impact its market dynamics further.
Raw Material for Patiromer Production
According to the patiromer production plant project report, the key raw materials used in the production of patiromer include methyl-2-fluoroacrylate, 1,7-octadiene, and divinylbenzene.
Production Process of Patiromer
The extensive patiromer production cost report consists of the following major industrial production process:
- From methyl-2-fluoroacrylate: The production process of patiromer involves several steps. It starts with suspension polymerisation of methyl-2-fluoroacrylate, 1,7-octadiene, and divinylbenzene with polysorbate 20 stabiliser. This is followed by filtration, washing with water and acetone, and vacuum drying get the methyl ester polymer. The polymer is hydrolysed with lithium hydroxide in isopropyl alcohol and water to form the lithium carboxylate salt. This is then exchanged to calcium salt by treatment with calcium chloride in water, filtered, washed and dried to give patiromer calcium.
Patiromer is a non-absorbed, cation exchange polymer used as patiromer sorbitex calcium. It consists of the active moiety patiromer, a cross-linked copolymer of 2-fluoroacrylic acid with divinylbenzene and 1,7-octadiene combined with a calcium-sorbitol counterion. It appears as an amorphous, free-flowing off-white to light brown powder made of individual spherical beads. It is fully insoluble in water, HCl, n-heptane, methanol, and other common solvents. It enables potassium binding via calcium exchange in the gastrointestinal tract. It has no defined molecular weight because of its polymeric nature, but it offers high binding capacity per site compared to alternatives like polystyrene sulfonate. Its formulations include xanthan gum as an inactive ingredient for oral suspension.